pamidronate has been researched along with Conus Medullaris Syndrome in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 9.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 9.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 5.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy." | 5.08 | Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996) |
| ", oral clodronate and intravenous pamidronate and zoledronic acid) can inhibit osteoclast-mediated osteolysis, thereby reducing the risk of SREs, ameliorating bone pain, and potentially prolonging survival in patients with MM." | 4.87 | Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. ( Berenson, J; Dimopoulos, MA; Terpos, E, 2011) |
| "Our results show that the majority of patients with breast cancer, who develop bony metastases in Newfoundland and Labrador, are initially treated with the bisphosphonate, pamidronate." | 3.79 | Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. ( Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M, 2013) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "To find an effective symptomatic treatment for osteogenesis imperfecta (OI)." | 1.31 | Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. ( Aström, E; Söderhäll, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Qiao, D | 1 |
| Lu, Y | 1 |
| Curtis, D | 1 |
| Wen, X | 1 |
| Yao, Y | 1 |
| Zhao, H | 1 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 2 |
| Berenson, J | 1 |
| Murphy, L | 1 |
| McCarthy, J | 1 |
| McCrate, F | 1 |
| Laing, K | 1 |
| Powell, E | 1 |
| Seal, M | 1 |
| Edwards, S | 1 |
| Major, PP | 1 |
| Cook, R | 1 |
| Rosen, LS | 1 |
| Gordon, DH | 1 |
| Dugan, W | 1 |
| Major, P | 1 |
| Eisenberg, PD | 1 |
| Provencher, L | 1 |
| Kaminski, M | 1 |
| Simeone, J | 2 |
| Seaman, J | 2 |
| Chen, BL | 1 |
| Coleman, RE | 1 |
| Berenson, JR | 1 |
| Lichtenstein, A | 1 |
| Porter, L | 1 |
| Bordoni, R | 1 |
| George, S | 1 |
| Lipton, A | 2 |
| Keller, A | 1 |
| Ballester, O | 1 |
| Kovacs, MJ | 1 |
| Blacklock, HA | 1 |
| Bell, R | 1 |
| Reitsma, DJ | 1 |
| Heffernan, M | 1 |
| Knight, RD | 1 |
| Harvey, HA | 1 |
| Paule, B | 1 |
| Clerc, D | 1 |
| Brion, N | 1 |
| Godfrin, B | 1 |
| Alvarez, M | 1 |
| Laroche, M | 1 |
| Ollier, S | 1 |
| Dingremont, C | 1 |
| Sailler, L | 1 |
| Arlet, P | 1 |
| Aström, E | 1 |
| Söderhäll, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study[NCT02480634] | Phase 4 | 280 participants (Anticipated) | Interventional | 2019-06-30 | Not yet recruiting | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916] | 17 participants | Observational | 1999-03-31 | Completed | |||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pamidronate and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; | 2015 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinica | 2011 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; | 2002 |
4 trials available for pamidronate and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Re | 2004 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H | 1996 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
[Analgesic effect of a diphosphonate perfusion during the acute phase of vertebral compression in the elderly subject].
Topics: Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates; Female; Hu | 2000 |
4 other studies available for pamidronate and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bre | 2013 |
[Biosphonates in oncology].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Neoplasms; Osteolysis; Pain | 2000 |
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Biomarkers; Bone Density; Bone Remodeling; Child; Child, Prescho | 2002 |